The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors.
Paolo Andrea Zucali
No relevant relationships to disclose
Matteo Simonelli
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Elena Lorenzi
No relevant relationships to disclose
Matteo Perrino
No relevant relationships to disclose
Monica Bertossi
No relevant relationships to disclose
Luca Balzarini
No relevant relationships to disclose
Cristina Bonifacio
No relevant relationships to disclose
Antonio Lambiase
Employment or Leadership Position - MolMed S.p.A.
Claudio Bordignon
Employment or Leadership Position - MolMed S.p.A.
Armando Santoro
No relevant relationships to disclose